Phenprocoumon is a long-acting anticoagulant to be taken by mouth, and a coumarin derivative. It acts as a vitamin K antagonist and inhibits blood clotting by blocking synthesis of coagulation factors II, VII, IX and X. Mechanistically it inhibits the vitamin K epoxide reductase complex, preventing gamma carboxylation of these clotting factors and producing an anticoagulant state that requires several days to reach full effect. Phenprocoumon is highly protein bound, predominantly to albumin, and is metabolized hepatically by cytochrome P450 enzymes including CYP2C9 and CYP3A4 to hydroxylated and conjugated metabolites that are eliminated in urine and bile. The drug exhibits a long and variable elimination half-life, typically longer than that of warfarin, which supports once-daily oral dosing but also contributes to prolonged anticoagulant effects after dose changes. Clinical use requires regular monitoring of the international normalized ratio INR, dose adjustment for renal and hepatic impairment and attention to interactions with other medicines and dietary vitamin K intake. Reversal in overanticoagulation is effected by vitamin K administration and, in urgent bleeding situations, by prothrombin complex concentrates or plasma according to guidelines.
Parent: Phenprocoumon
Pharmaceutical quality control of phenprocoumon typically monitors a defined set of related substances and degradation products, with individual specified impurities commonly limited to 0.1 to 0.2 percent (w/w) and total impurities limited to 0.5 to 1.0 percent (w/w) depending on the product specification and regulatory monograph. Typical related compounds and process- or metabolism-related species include hydroxylated isomers such as 4-hydroxyphenprocoumon and 3-hydroxyphenprocoumon, desalkyl or demethyl derivatives, positional isomers of the phenylpropyl side chain, and trace coupling or dimerization products; these are generally controlled at or below the individual limits cited above. Residual solvents are controlled per ICH Q3C with typical class II/III solvents restricted to parts per million limits, and elemental impurities are controlled per ICH Q3D. Identification and quantitation are performed by validated HPLC with orthogonal confirmation by LC-MS for structural assignment, plus GC for volatile impurities and ICP-MS or AAS for metal content.
Phenprocoumon is used to prevent and treat thromboembolic events including prevention of stroke in patients with atrial fibrillation, treatment and secondary prevention of venous thromboembolism, and prevention of thrombosis in patients with prosthetic heart valves. Therapy requires individualized dosing guided by INR monitoring and consideration of bleeding risk, comorbidities, and interacting drugs.
No, phenprocoumon and warfarin are both vitamin K antagonists but they are distinct chemical entities with different pharmacokinetic profiles. Phenprocoumon has a substantially longer and more variable elimination half-life than warfarin, which affects onset and offset of anticoagulant effect and dosing strategies. Clinically they are not interchangeable without expert supervision, because dosing, monitoring frequency and interaction profiles differ.
